Thymosin Alpha-1 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
FDA-approved as orphan drug for melanoma, DiGeorge syndrome, chronic hepatitis B, and hepatocellular carcinoma. Clinical trials ongoing for lung cancer, hepatitis C, HIV, and COVID-19. Approved in 35 countries. Thymosin Alpha-1 is fda-approved (zadaxin) for specific cancer and hepatitis indications. prescription medication.
What Does the Research Say About Thymosin Alpha-1?
FDA-approved as orphan drug for melanoma, DiGeorge syndrome, chronic hepatitis B, and hepatocellular carcinoma. Clinical trials ongoing for lung cancer, hepatitis C, HIV, and COVID-19. Approved in 35 countries.
Thymosin Alpha-1 (Thymosin alpha 1 (28-amino acid peptide)) is a Thymic peptide, immunomodulator. Research interest has focused on its potential effects on immune activation, T-cell function enhancement, antiviral response, cancer immunotherapy adjuvant.
What Is the Evidence for Thymosin Alpha-1's Mechanism?
Engages Toll-like receptors (TLR) on myeloid and plasmacytoid dendritic cells, triggering MyD88-dependent signaling cascades. Drives IL-2 production, IFN-gamma stimulation, and T lymphocyte/NK cell activation while promoting thymopoiesis. Simultaneously suppresses pro-inflammatory IL-6/TNF-alpha while enhancing anti-inflammatory IL-10.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for Thymosin Alpha-1?
FDA-approved as orphan drug for melanoma, DiGeorge syndrome, chronic hepatitis B, and hepatocellular carcinoma. Clinical trials ongoing for lung cancer, hepatitis C, HIV, and COVID-19. Approved in 35 countries.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, Thymosin Alpha-1 has shown encouraging results.
What Does the Safety Research Show?
Well-tolerated. Local injection site reactions most common. Safe in liver disease, cancer, and autoimmune conditions. No significant organ toxicity.
Thymosin Alpha-1 is fda-approved (zadaxin) for specific cancer and hepatitis indications. prescription medication.
What Makes Thymosin Alpha-1 Unique in Research?
The only FDA-approved thymic peptide with specific orphan drug indications — approved in 35 countries, making it the most globally validated immune peptide therapeutic.
This differentiator is important because it means Thymosin Alpha-1 fills a role that other compounds in its class may not fully replicate.
Bottom Line on Thymosin Alpha-1 Research
The evidence base for Thymosin Alpha-1 is growing. Key research areas include immune activation, T-cell function enhancement, antiviral response, cancer immunotherapy adjuvant.
Stay current with PubMed searches for Thymosin Alpha-1 for the latest publications.
Complete Guide
Thymosin Alpha-1 : Benefits, Dosage, Side Effects & Research
Related Reading
- Thymosin Alpha-1 Dosage Guide
- Thymosin Alpha-1 Benefits
- Thymosin Alpha-1 Side Effects
- Thymosin Alpha-1 Stacking Guide
- Thymosin Alpha-1 Cycle Guide
- AOD-9604 Complete Guide
Calculate Your Thymosin Alpha-1 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Thymosin Alpha-1.
Open Calculator →Research-Grade Sourcing
If you're going to research Thymosin Alpha-1, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 (Thymosin alpha 1 (28-amino acid peptide)) is a Thymic peptide, immunomodulator. Naturally occurring peptide isolated from thymus gland; synthetic form (thymalfasin/Zadaxin) developed for immune enhancement. It is researched for immune activation, T-cell function enhancement, antiviral response, cancer immunotherapy adjuvant.
What is the recommended Thymosin Alpha-1 dosage?
Common dosages: 1.6-6.4 mg per dose administered twice weekly via subcutaneous injection. Cycle length: 5-7 day injection cycles, repeated as needed. Half-life: not established. Use our peptide calculator for exact reconstitution math.
What are the side effects of Thymosin Alpha-1?
Well-tolerated. Local injection site reactions most common. Safe in liver disease, cancer, and autoimmune conditions. No significant organ toxicity.
Is Thymosin Alpha-1 safe?
Thymosin Alpha-1 has shown a favorable safety profile in research. FDA-approved (Zadaxin) for specific cancer and hepatitis indications. Prescription medication. All research should follow appropriate safety protocols.